Green light from NICE for NSCLC immunotherapy; Pan-Cancer Atlas data and 40 myeloma genes unearthed.
Browsing: Disease Area > Hematologic
In this joint interview we delve deeper into the news story to find out both the clinician’s and patient’s perspective on the recent recommendation of ixazomib for NHS distribution.
John Ellwood discusses the treatment he underwent following his diagnosis with myeloma.
A new drug, termed ixazomib, is to be used in combination with standard treatments and has been made available on the Cancer Drug Fund.
Researchers from the Dana-Farber Cancer Institute (MA, USA) have conducted the largest genomic analysis of patients with smoldering multiple myeloma –a precursor to multiple myeloma. The results may offer a new insight into the mechanism of multiple myeloma progression.
Results from a pair of clinical trials evaluating the CAR-T cell therapy Kymriah™ have demonstrated long-lasting remissions in non-Hodgkin’s lymphoma patients.
Researchers at The institute of Cancer Research (London, UK) have identified six genetic changes that increase the risk of developing Hodgkin lymphoma.
A genetics study has unearthed an unexpected new drug target for acute myeloid leukaemia that could open new avenues to develop effective treatments.
Discover the importance of DNA methylation changes in the identification of potential biomarkers relevant for clinical follow-up and personalized medicine of chronic lymphocytic leukemia.
In this research article from the Journal of Comparative Effectiveness Research find out about the characteristics and treatment patterns among US patients with hairy cell leukemia.